Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Status:
Terminated
Trial end date:
2018-10-03
Target enrollment:
Participant gender:
Summary
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of
carfilzomib that can be given in combination with lenalidomide and rituximab to patients with
relapsed or refractory B-cell non-hodgkin lymphoma.
The goal of Part 2 of this study is to learn if the drug combination can help to control
B-cell non-hodgkin lymphoma.
The safety of this drug combination will be studied in both parts.
Carfilzomib is designed to keep cancer cells from repairing themselves. If the cancer cells
cannot repair themselves, this may cause them to die.
Lenalidomide is designed to change the body's immune system. It may also interfere with the
development of tiny blood vessels that help support tumor growth. This may decrease the
growth of cancer cells.
Rituximab is designed to attach to cancer cells and damage them, which may cause the cancer
cells to die. It is also designed to cause the immune system to attack cancer cells.